Aberrant p53 fuels macrophage immunoregulatory polarization and refractory clinical outcome in urothelial carcinoma
Journal for ImmunoTherapy of Cancer · 2026
DOI: 10.1136/jitc-2025-014408 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2026. Verfasst von Yawei Ding und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, School of Basic Medical Sciences, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Tumor Suppressor Protein p53, Tumor-Associated Macrophages, Macrophages, Urinary Bladder Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: China Postdoctoral Science Foundation, National Natural Science Foundation of China, Shanghai Sailing Program.
Abstract (Originalsprache)
Background
Urothelial carcinoma (UC) exhibits extensive infiltration of tumor-associated macrophages (TAMs). As the most frequently altered gene in UC, TP53 is recognized not only as a guardian of genomic integrity, but also as a potential architect of the tumor immune microenvironment (TIME). However, how aberrant p53 status, comprising TP53 mutation ( TP53 Mut ) and p53 abnormal expression (p53 Abn ), correlates with TAM phenotypic and functional heterogeneity and their reciprocal interactions within the TIME landscape remains incompletely defined.
Methods
This study integrated single-cell RNA sequencing, immunohistochemistry, and flow cytometry to delineate TAM phenotypes and map distinct immune landscapes stratified by p53 status. Clinical relevance was assessed in a multicohort dataset of 962 patients with UC with comprehensive clinicopathological annotations.
Results
Single-cell profiling revealed distinct TAM subsets closely linked to p53 status. Interferon-primed TAMs, marked by CXCL9 , CXCL10 , CXCL11 and IDO1 , predominated in p53 wild-type (p53 WT ) tumors, whereas immune regulatory TAMs (Reg-TAMs), marked by SPP1 , MARCO , SLC2A1 and INHBA, were enriched in p53 Abn tumors. This divergent distribution highlighted a profound, p53-associated TAM heterogeneity. Clinically, high TAMs infiltration was consistently associated with worse overall survival predominantly in p53 Abn or TP53 Mut patients across three independent cohorts (Zhongshan Hospital, Fudan University Shanghai Cancer Center and The Cancer Genome Atlas). Furthermore, high TAMs infiltration correlated with poorer responses to both platinum-based chemotherapy and anti-programmed cell death-ligand 1 immunotherapy specifically in the p53 Abn or TP53 Mut subgroup. Notably, aberrant p53 status was strongly coupled with a distinct metabolic reprogramming in TAMs, favoring lipid catabolism and immunoregulatory polarization. Trajectory analysis revealed a skewed differentiation axis in p53 Abn tumors toward terminally differentiated Reg-TAMs. Immunohistochemistry and flow cytometry validated increased immunosuppressive TAM subsets in p53 Abn UC. Additionally, p53 Abn tumors exhibited an altered CD4 + T-cell landscape, enriched for suppressive subsets (regulatory, exhausted, and metallothionein-expressing T cells) coexisting with Reg-TAMs, potentially associated with immune suppression via the predicted SPP1-CD44 axis.
Conclusions
In UC, aberrant p53 status correlates with a remodeled TIME, characterized by metabolically reprogrammed, immunosuppressive TAMs. These TAMs co-evolve with suppressive CD4 + T cells, suggesting a coordinated immunosuppressive network potentially involving SPP1-CD44 signaling. Together, this specific genotype-phenotype coupling delineates a profoundly immunosuppressive ecosystem that likely impedes immune clearance and limits therapeutic efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
- National Health Commission Key Laboratory of Glycoconjugate Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
- Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
- Department of Urology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
- Department of Urology, Urologic Surgery Center, Xinqiao Hospital, Third Military Medical University (Army Medical University), Chongqing, China.
- Department of Urology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Förderung
- China Postdoctoral Science Foundation
- National Natural Science Foundation of China
- Shanghai Sailing Program
- Shanghai Anticancer Association EYAS PROJECT
- Fudan University Shanghai Cancer Center for Outstanding Youth Scholars Foundation
- Youth Foundation of Zhongshan Hospital affiliated with Fudan University
- Key Project of Young Doctor Incubation Program of the Second Affiliated Hospital of Army Medical University
- Beijing Xisike Clinical Oncology Research Foundation
Zitieren
APA
Ding, Y., Jin, K., Su, X., Zhang, L., Liu, Z., Sun, J., Wu, Y., Shi, J., Zeng, H., Liu, H., Zhu, Y., Xu, L., Wang, Z., Chang, Y., Zhang, W., Xu, J., & Shanghai Urothelial Carcinoma Research Group (SUCRG) (2026). Aberrant p53 fuels macrophage immunoregulatory polarization and refractory clinical outcome in urothelial carcinoma. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2025-014408
Vancouver
Ding Y, Jin K, Su X, Zhang L, Liu Z, Sun J, et al. Aberrant p53 fuels macrophage immunoregulatory polarization and refractory clinical outcome in urothelial carcinoma. Journal for ImmunoTherapy of Cancer. 2026. doi:10.1136/jitc-2025-014408
BibTeX
@article{Ding2026,
author = {Ding, Yawei and Jin, Kaifeng and Su, Xiaohe and Zhang, Lingkai and Liu, Zhaopei and Sun, Jiaxing and Wu, Yuzhen and Shi, Jinming and Zeng, Han and Liu, Hailong and Zhu, Yu and Xu, Le and Wang, Zewei and Chang, Yuan and Zhang, Weijuan and Xu, Jiejie and Shanghai Urothelial Carcinoma Research Group (SUCRG), Shanghai Urothelial Carcinoma Research Group (SUCRG)},
title = {Aberrant p53 fuels macrophage immunoregulatory polarization and refractory clinical outcome in urothelial carcinoma},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2026},
doi = {10.1136/jitc-2025-014408}
}
EUVIMED